In our study, we first assessed the TTB by estimating the timing until the treatment effect first or consistently reached statistical significance based on a P < .05, which was also adopted in prior analyses in DELIVER,30 DAPA-HF,31 and SOLOIST-WHF.32 Similarly, our result suggested early and sustained clinical benefits from SGLT2 inhibitors in the range of 1 month. The gene discussed is SLC5A2; the disease is hydrops fetalis.